anastrozole has been researched along with Benign Neoplasms, Brain in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 9.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 7.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| " MK-2206 in combination with anastrozole is being further evaluated in a phase II neoadjuvant trial for newly diagnosed ER(+)HER2(-) breast cancer." | 5.22 | A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. ( Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C, 2016) |
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 5.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 3.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "MRI study revealed brain metastases with a diameter of 1 cm in her right midbrain in April 2005, so a gamma knife radio-surgery was performed." | 1.33 | [Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, CX | 1 |
| Sanchez, C | 1 |
| Gao, F | 1 |
| Crowder, R | 1 |
| Naughton, M | 1 |
| Pluard, T | 1 |
| Creekmore, A | 1 |
| Guo, Z | 1 |
| Hoog, J | 1 |
| Lockhart, AC | 1 |
| Doyle, A | 1 |
| Erlichman, C | 1 |
| Ellis, MJ | 1 |
| Saha, P | 1 |
| Amico, AL | 1 |
| Olopade, OI | 1 |
| Campos, SM | 1 |
| Guastalla, JP | 1 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Winer, EP | 1 |
| Cameron, DA | 1 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Arnould, L | 1 |
| Fumoleau, P | 1 |
| Mukai, T | 1 |
| Hikino, H | 1 |
| Koike, M | 1 |
| Murata, Y | 1 |
| Hojo, S | 1 |
| Maeura, Y | 1 |
| Yoshioka, S | 1 |
| Fujie, Y | 1 |
| Fukunaga, H | 1 |
| Okada, Y | 1 |
| Ota, H | 1 |
| Endo, W | 1 |
1 review available for anastrozole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
2 trials available for anastrozole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2016 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
3 other studies available for anastrozole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2012 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2006 |